NFA
RPRX icon

Northwest Financial Advisors’s Royalty Pharma RPRX Stock Holding History

Northwest Financial Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-120
Closed -$3.4K – 442
2024
Q3 		$3.4K Buy
+120
New +$3.32K ﹤0.01% 469
2024
Q1 		– Sell
-120
Closed -$3.37K – 421
2023
Q4 		$3.37K Buy
+120
New +$3.3K ﹤0.01% 463

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northwest Financial Advisors's RPRX Position: Q4 2024 in Review

Northwest Financial Advisors sold out of Royalty Pharma (RPRX) in Q4 2024, closing a stake of 120 shares — an estimated $3.4K sold.

Northwest Financial Advisors first reported a position in RPRX in Q4 2023 and held it in 2 quarters. The position peaked at $3.4K in Q3 2024. 417 funds tracked by Wall St. Rank hold RPRX as of Q4 2024.

  • Northwest Financial Advisors reported no remaining Royalty Pharma position as of Q4 2024 after selling out during the quarter.
  • Northwest Financial Advisors sold 120 Royalty Pharma shares in Q4 2024, an estimated $3.4K.
  • Northwest Financial Advisors first reported a position in Royalty Pharma in Q4 2023 and held it in 2 quarters.
  • Northwest Financial Advisors's Royalty Pharma position peaked at $3.4K in Q3 2024.
  • 417 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2024.

Based on Northwest Financial Advisors's 13F filing for Q4 2024, filed 22 Jan 2025.